{
  "id": 6774452,
  "title": "FDA extends review of Exelixis' colorectal cancer drug candidate",
  "url": "https://urgent.news/2026/09/11/fda-extends-review-of-exelixis-colorectal-cancer-drug-candidate",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-11T16:02:17.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/fda-extends-review-of-exelixis-colorectal-cancer-drug-candidate/"
  },
  "original_language": "en",
  "account": null,
  "summary": "California-based drug developer Exelixis submitted new safety and efficacy data on its potential treatment of metastatic colorectal cancer (mCRC) to the FDA. The new data led to a three-month extension in the agency's review, the ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}